期刊文献+

阿加曲班联合尤瑞克林治疗进展性脑梗死的疗效与安全性探讨

Discussion on the efficacy and safety of argatroban combined with urinary Kallidinogenase in thetreatment of progressive cerebral infarction
在线阅读 免费下载
收藏 分享 导出
摘要 目的分析进展性脑梗死患者采用阿加曲班联合尤瑞克林进行治疗的临床效果以及安全性。方法116例进展性脑梗死患者,随机分为实验组与对照组,各58例。对照组采用尤瑞克林进行治疗,实验组在对照组基础上联合阿加曲班进行治疗。对比两组治疗前后美国国立卫生研究院卒中量表(NIHSS)评分、Barthel指数(MBI)评分、改良Rankin量表(mRS)评分及不良反应发生情况。结果治疗后,实验组NIHSS评分(10.42±1.25)分、mRS评分(1.50±0.42)分低于对照组的(11.32±1.48)、(1.70±0.27)分,MBI评分(68.62±8.39)分高于对照组的(64.27±8.61)分,差异均有统计学意义(P<0.05)。实验组不良反应总发生率3.4%与对照组的6.9%对比,差异无统计学意义(P>0.05)。结论进展性脑梗死患者采用阿加曲班联合尤瑞克林进行治疗的临床效果较单独使用尤瑞克林更为有效,患者神经功能恢复明显,生活质量得以提升,且该药物联合使用安全性高,具有广泛应用于临床的价值。 Objective To analyze the clinical effect and safety of argatroban combined with urinary kallidinogenase in the treatment of progressive cerebral infarction.Methods A total of 116 progressive cerebral infarction patients were randomly divided into experimental group and control group,with 58 cases in each group.The control group was treated by urinary kallidinogenase,and the experimental group was treated by argatroban on the basis of the control group.The National Institutes of Health stroke scale(NIHSS)score,modified Barthel index(MBI)score,modified Rankin scale(mRS)score before and after treatment and occurrence of adverse reactions were compared between the two groups.Results After treatment,NIHSS score(10.42±1.25)points and mRS score(1.5±0.42)points of the experimental group were lower than those of the control group(11.32±1.48)and(1.7±0.27)points,and MBI score(68.62±8.39)points was higher than that of the control group(64.27±8.61)points,and the difference was statistically significant(P<0.05).The incidence of adverse reactions 3.4%of the experimental group had no statistically significant difference compared with that of the control group 6.9%(P>0.05).Conclusion Argatroban combined with urinary kallidinogenase shows better clinical effect for patients with progressive cerebral infarction than of urinary kallidinogenase alone,which can obviously improve the neurological function and quality of life of patients with high safety.It can be widely used in clinical work.
作者 李妙嫦 梁玉婵 黄根林 LI Miao-chang;LIANG Yu-chan;HUANG Gen-lin(Zhaoqing First People’s Hospital,Zhaoqing 526000,China)
出处 《中国现代药物应用》 2020年第11期107-109,共3页 Chinese Journal of Modern Drug Application
关键词 阿加曲班 尤瑞克林 脑梗死 疗效 安全性 Argatroban Urinary kallidinogenase Cerebral infarction Efficacy Safety
  • 相关文献

参考文献12

二级参考文献125

  • 1朱晓冬,王景华,程焱.阿加曲班治疗急性脑梗死的有效性和安全性研究[J].天津医药,2006,34(6):376-378. 被引量:25
  • 2各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:29399
  • 3许俊堂.阿加曲班临床应用的进展[J].血栓与止血学,2007,13(4):180-182. 被引量:42
  • 4Ghandehari K. Challenging comparison of stroke scales[J]. J Res Med Sci, 2013, 18(10): 906- 910. 被引量:1
  • 5Nye BR, Hyde CE, Tsivgoulis G, et al. Slim stroke scales for ass- essing patients with acute stroke: ease of use or loss of valuable assessment data[J]? Am J Crit Care, 2012, 21(6): 442- 447. 被引量:1
  • 6Balucani C, Levine SR. Mild stroke and rapidly improving symp- toms: it's not always a happy ending[J]. Stroke, 201 1, 42(1 1): 3005-3007. 被引量:1
  • 7Khatri P, Kleindorfer DO, Yeatts SD, et al. Strokes with minor s- ymptoms: an exploratory analysis of the National Institute of Ne- urological Disorders and Stroke recombinant tissue plasm- inogen activator trials[J]. Stroke, 2010, 41(11): 2581-2586. 被引量:1
  • 8Fonarow GC, Saver JL, Smith EE, et al. Relationship of National Institutes of Health Stroke Scale to 30-day mortality in medi- care beneficiaries with acute ischemic stroke[J]. J Am Heart As- soc, 2012, 1(1): 42-50. 被引量:1
  • 9Smith EE, Shobha N, Dai D, et al. A risk score for in-hospital death in patients admitted with ischemic or hemorrhagic stroke[J]. J Am Heart Assoc, 2013, 2(1): e005207- e005207. 被引量:1
  • 10Mishra NK, Albers GW, Christensen S, et al. Comparison of ma- gnetic resonance imaging mismatch criteria to select patients for endovascular stroke therapy[J]. Stroke, 2014, 45(5): 1369-1374. 被引量:1

共引文献144

论文智能改写系统
维普数据出版直通车
投稿分析
职称考试

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈